Athersys (ATHX) Reports Q1 EPS of $0.06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Athersys Reports First Quarter 2016 Results
May 5, 2016 4:10 PM EDTCLEVELAND, May 05, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) today announced its financial results for the three months ended March 31, 2016.
Highlights of the first quarter of 2016 and recent events include:
Announced positive one-year follow-up results from the Phase 2 study of MultiStem® cell therapy to treat ischemic stroke demonstrating progressive improvements and significantly higher rate of excellent outcomes at one year for MultiStem-treated patients with greater benefits for patients receiving MultiStem treatment within 36 hours of the stroke;Established collaboration with HEALIOS K.K. (Healios) to develop MultiStem cell... More